{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:09:15Z","timestamp":1740161355233,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychiatr"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Auf Grund seiner unvergleichbaren Wirksamkeit bei therapieresistenten schizophrenen St\u00f6rungen ist der Abbruch einer Behandlung mit Clozapin h\u00e4ufig mit einer erheblichen Verschlechterung der Krankheitssymptomatik, aber auch mit einem erh\u00f6hten Suizidrisiko verbunden. Ziel der vorliegenden \u00dcbersichtsarbeit ist es, auf Basis aktueller Fachliteratur verschiedene Monitoring-Empfehlungen zusammen zu fassen, um diese Therapie gegebenenfalls trotz auftretender unerw\u00fcnschter Arzneimittelwirkungen (UAW) fortsetzen zu k\u00f6nnen. Des Weiteren wird ausgearbeitet, wann eine unterbrochene Therapie mit Clozapin wieder aufgenommen werden kann (Rechallenge) und wann ein definitiver Behandlungsabbruch erfolgen muss.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Die Datenbank Medline sowie die Guideline for the use of clozapine 2013 der Netherlands Clozapine Collaboration Group und die S3-Behandlungsleitlinie Schizophrenie der Deutschen Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde\u00a0e.V. wurden nach relevanter Literatur untersucht, die letzte Abfrage erfolgte am 28.04.2023.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Resultate<\/jats:title>\n                <jats:p>Bei Entwicklung einer Agranulozytose oder einer Kardiomyopathie muss die Behandlung mit Clozapin beendet werden und sollte auch im weiteren Verlauf nicht wieder aufgenommen werden. Dem gegen\u00fcber kann eine auf Grund einer Myokarditis bzw. einer unter der Behandlung auftretenden Verl\u00e4ngerung der QTc-Zeit abgebrochene Behandlung mit Clozapin bei regelrechter linksventrikul\u00e4rer Funktion bzw. nach Normalisierung der QTc-Zeit gegebenenfalls fortgesetzt werden. Andere UAW stellen in der Regel keine absolute Kontraindikation f\u00fcr eine Rechallenge dar, erfordern jedoch h\u00e4ufig den adjuvanten Einsatz zus\u00e4tzlicher pharmakologischer und nicht-pharmakologischer Ma\u00dfnahmen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Unter Ber\u00fccksichtigung verschiedener Monitoring-Empfehlungen kann die Beendigung einer Behandlung mit Clozapin h\u00e4ufig verhindert bzw. eine auf Grund von UAW abgebrochene Behandlung mit Clozapin wieder aufgenommen werden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40211-023-00473-0","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T10:02:35Z","timestamp":1688119355000},"page":"130-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sicherheitsaspekte bei der Behandlung mit Clozapin","Safety aspects during treatment with clozapine."],"prefix":"10.1007","volume":"37","author":[{"given":"Stefan J.","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-4258","authenticated-orcid":false,"given":"Alex","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"1","key":"473_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0957154X07070335","volume":"18","author":"J Crilly","year":"2007","unstructured":"Crilly\u00a0J. The history of clozapine and its emergence in the US market: a\u00a0review and analysis. Hist Psychiatry. 2007;18(1):39\u201360.","journal-title":"Hist Psychiatry"},{"issue":"1","key":"473_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1600-0447.2011.01776.x","volume":"125","author":"NB Pai","year":"2012","unstructured":"Pai\u00a0NB, Vella\u00a0S. Reason for clozapine cessation. Acta Psychiatr Scand. 2012;125(1):39\u201344.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"473_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4088\/JCP.12r08064","volume":"74","author":"J Nielsen","year":"2013","unstructured":"Nielsen\u00a0J, Correll\u00a0CU, Manu\u00a0P, Kane\u00a0JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J\u00a0Clin Psychiatry. 2013;74(6):603\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"473_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2165\/00023210-200519120-00006","volume":"19","author":"N Sepp\u00e4l\u00e4","year":"2005","unstructured":"Sepp\u00e4l\u00e4\u00a0N, Kovio\u00a0C, Leinonen\u00a0E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs. 2005;19(12):1049\u201355.","journal-title":"CNS Drugs"},{"issue":"6","key":"473_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/YIC.0b013e32834ab34c","volume":"26","author":"A Krivoy","year":"2011","unstructured":"Krivoy\u00a0A, Malka\u00a0L, Fischel\u00a0T, Weizman\u00a0A, Valevski\u00a0A. Predictors of clozapine discontinuation in patients with schizophrenia. Int Clin Psychopharmacol. 2011;26(6):311\u20135.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"473_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0269881108100320","volume":"24","author":"J Nielsen","year":"2010","unstructured":"Nielsen\u00a0J, Dahm\u00a0M, Lublin\u00a0H, Taylor\u00a0D. Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment. J\u00a0Psychopharmacol. 2010;24(7):965\u201371.","journal-title":"J Psychopharmacol"},{"key":"473_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1192\/pb.27.6.211","volume":"27","author":"E Whiskey","year":"2003","unstructured":"Whiskey\u00a0E, Wykes\u00a0T, Duncan-McConnell\u00a0D, Haworth\u00a0E, Walsh\u00a0N, Hastilow\u00a0S. Continuation of clozapine treatment: practice makes perfect. Psychiatr bull. 2003;27:211\u20133.","journal-title":"Psychiatr bull"},{"issue":"4","key":"473_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000507638","volume":"89","author":"J de Leon","year":"2020","unstructured":"de Leon\u00a0J, Ruan\u00a0CJ, Schoretsanitis\u00a0G, De Las Cuevas\u00a0C. A Rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89(4):200\u201314.","journal-title":"Psychother Psychosom"},{"key":"473_CR9","doi-asserted-by":"crossref","unstructured":"Berger SJ. Sicherheitsaspekte bei der Behandlung mit Clozapin. Medizinische Universit\u00e4t Innsbruck: Diplomarbeit; 2022.","DOI":"10.1007\/s40211-023-00473-0"},{"issue":"2","key":"473_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1625-6388","volume":"55","author":"J de Leon","year":"2022","unstructured":"de Leon\u00a0J, Schoretsanitis\u00a0G, Smith\u00a0RL, Molden\u00a0E, Solismaa\u00a0A, Sepp\u00e4l\u00e4\u00a0N, et al. An international adult guideline for making Clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and Clozapine levels. Pharmacopsychiatry. 2022;55(2):73\u201386.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"473_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/wps.20707","volume":"19","author":"J de Leon","year":"2020","unstructured":"de Leon\u00a0J, Sanz\u00a0EJ, Nor\u00e9n\u00a0GN, De Las Cuevas\u00a0C. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry. 2020;19(1):120\u20131.","journal-title":"World Psychiatry"},{"issue":"4","key":"473_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.9758\/cpn.2016.14.4.323","volume":"14","author":"N Kar","year":"2016","unstructured":"Kar\u00a0N, Barreto\u00a0S, Chandavarkar\u00a0R. Clozapine monitoring in clinical practice: beyond the mandatory requirement. Clin Psychopharmacol Neurosci. 2016;14(4):323\u20139.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"6","key":"473_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/JCP.0000000000001605","volume":"42","author":"K Kim","year":"2022","unstructured":"Kim\u00a0K, Kim\u00a0YS, Joo\u00a0EJ, Kim\u00a0EJ, Bhang\u00a0SY, Choi\u00a0JW, Jeong\u00a0JH, Lee\u00a0KY. Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses. J\u00a0Clin Psychopharmacol. 2022;42(6):536\u201343.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"473_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","volume":"30","author":"SJ Haas","year":"2007","unstructured":"Haas\u00a0SJ, Hill\u00a0R, Krum\u00a0H, Liew\u00a0D, Tonkin\u00a0A, Demos\u00a0L, et al. Clozapine-associated myocarditis: a\u00a0review of 116\u00a0cases of suspected myocarditis associated with the use of clozapine in Australia during 1993\u20132003. Drug Saf. 2007;30(1):47\u201357.","journal-title":"Drug Saf"},{"issue":"6","key":"473_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/00048674.2011.572852","volume":"45","author":"KJ Ronaldson","year":"2011","unstructured":"Ronaldson\u00a0KJ, Fitzgerald\u00a0PB, Taylor\u00a0AJ, Topliss\u00a0DJ, McNeil\u00a0JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75\u00a0cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458\u201365.","journal-title":"Aust N Z J Psychiatry"},{"issue":"11","key":"473_CR16","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2004.11.069","volume":"45","author":"H Abdel-Aty","year":"2005","unstructured":"Abdel-Aty\u00a0H, Boy\u00e9\u00a0P, Zagrosek\u00a0A, Wassmuth\u00a0R, Kumar\u00a0A, Messroghli\u00a0D, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J\u00a0Am Coll Cardiol. 2005;45(11):1815\u201322.","journal-title":"J Am Coll Cardiol"},{"issue":"933","key":"473_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/pmj.79.933.412","volume":"79","author":"MA Tanner","year":"2003","unstructured":"Tanner\u00a0MA, Culling\u00a0W. Clozapine associated dilated cardiomyopathy. Postgrad Med\u00a0J. 2003;79(933):412\u20133.","journal-title":"Postgrad Med J"},{"issue":"6","key":"473_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/JCP.0b013e318234ee66","volume":"31","author":"C Rostagno","year":"2011","unstructured":"Rostagno\u00a0C, Domenichetti\u00a0S, Pastorelli\u00a0F, Gensini\u00a0GF. Usefulness of NT-pro-BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity. J\u00a0Clin Psychopharmacol. 2011;31(6):712\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"473_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2261-14-67","volume":"14","author":"X Li","year":"2014","unstructured":"Li\u00a0X, Chen\u00a0C, Gan\u00a0F, Wang\u00a0Y, Ding\u00a0L, Hua\u00a0W. Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a\u00a0single-center cohort study. BMC Cardiovasc Disord. 2014;14:67.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"473_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/WNF.0b013e3181a620b2","volume":"32","author":"R Stryjer","year":"2009","unstructured":"Stryjer\u00a0R, Timinsky\u00a0I, Reznik\u00a0I, Weizman\u00a0A, Spivak\u00a0B. Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a\u00a0retrospective study. Clin Neuropharmacol. 2009;32(5):290\u20132.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"473_CR21","doi-asserted-by":"publisher","first-page":"e0156208","DOI":"10.1371\/journal.pone.0156208","volume":"11","author":"DJ Siskind","year":"2016","unstructured":"Siskind\u00a0DJ, Leung\u00a0J, Russell\u00a0AW, Wysoczanski\u00a0D, Kisely\u00a0S. Metformin for clozapine associated obesity: a\u00a0systematic review and meta-analysis. PLoS ONE. 2016;11(6):e156208.","journal-title":"PLoS ONE"},{"issue":"3","key":"473_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/acps.13462","volume":"146","author":"N Stogios","year":"2022","unstructured":"Stogios\u00a0N, Maksyutynska\u00a0K, Navagnanavel\u00a0J, Sanches\u00a0M, Powell\u00a0V, Gerretsen\u00a0P, Graff-Guerrero\u00a0A, Chintoh\u00a0AF, Foussias\u00a0G, Remington\u00a0G, Hahn\u00a0MK, Agarwal\u00a0SM. Metformin for the prevention of clozapine-induced weight gain: a\u00a0retrospective naturalistic cohort study. Acta Psychiatr Scand. 2022;146(3):190\u2013200.","journal-title":"Acta Psychiatr Scand"},{"issue":"10","key":"473_CR23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.4088\/JCP.11r06977","volume":"73","author":"D Cohen","year":"2012","unstructured":"Cohen\u00a0D, Bogers\u00a0JP, van Dijk\u00a0D, Bakker\u00a0B, Schulte\u00a0PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J\u00a0Clin Psychiatry. 2012;73(10):1307\u201312.","journal-title":"J Clin Psychiatry"},{"key":"473_CR24","unstructured":"Netherlands clozapine collaboration group. Guideline for the use of clozapine 2013 https:\/\/www.clozapinepluswerkgroep.nl\/wp-content\/uploads\/2013\/07\/Guideline-for-the-use-of-Clozapine-2013.pdf (28.04.2023)."},{"issue":"1","key":"473_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4088\/JCP.14m09301","volume":"77","author":"GC Hung","year":"2016","unstructured":"Hung\u00a0GC, Liu\u00a0HC, Yang\u00a0SY, Pan\u00a0CH, Liao\u00a0YT, Chen\u00a0CC, et al. Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a\u00a0nested case-control study. J\u00a0Clin Psychiatry. 2016;77(1):60\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"473_CR26","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1097\/MJT.0000000000000715","volume":"25","author":"P Manu","year":"2018","unstructured":"Manu\u00a0P, Lapitskaya\u00a0Y, Shaikh\u00a0A, Nielsen\u00a0J. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259\u00a0cases. Am J Ther. 2018;25(2):e218\u2013e23.","journal-title":"Am J Ther"},{"issue":"1","key":"473_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00023210-200721010-00003","volume":"21","author":"E Whiskey","year":"2007","unstructured":"Whiskey\u00a0E, Taylor\u00a0D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25\u201335.","journal-title":"CNS Drugs"},{"key":"473_CR28","doi-asserted-by":"publisher","first-page":"114247","DOI":"10.1016\/j.psychres.2021.114247","volume":"305","author":"N Richardson","year":"2021","unstructured":"Richardson\u00a0N, Greenway\u00a0SC, Bousman\u00a0CA. Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review. Psychiatry Res. 2021;305:114247. https:\/\/doi.org\/10.1016\/j.psychres.2021.114247.","journal-title":"Psychiatry Res"},{"key":"473_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijcard.2017.12.102","volume":"259","author":"BL Bellissima","year":"2018","unstructured":"Bellissima\u00a0BL, Tingle\u00a0MD, Cicovi\u0107\u00a0A, Alawami\u00a0M, Kenedi\u00a0C. A systematic review of clozapine-induced myocarditis. Int J Cardiol. 2018;259:122\u20139.","journal-title":"Int J Cardiol"},{"issue":"2","key":"473_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijcard.2014.07.103","volume":"176","author":"M Alawami","year":"2014","unstructured":"Alawami\u00a0M, Wasywich\u00a0C, Cicovic\u00a0A, Kenedi\u00a0C. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol. 2014;176(2):315\u201320.","journal-title":"Int J Cardiol"},{"issue":"3","key":"473_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/157488611797579230","volume":"6","author":"M Raja","year":"2011","unstructured":"Raja\u00a0M. Clozapine safety, 35\u00a0years later. Curr Drug Saf. 2011;6(3):164\u201384.","journal-title":"Curr Drug Saf"},{"issue":"2","key":"473_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M De Hert","year":"2011","unstructured":"De Hert\u00a0M, Detraux\u00a0J, van Winkel\u00a0R, Yu\u00a0W, Correll\u00a0CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114\u201326.","journal-title":"Nat Rev Endocrinol"},{"issue":"9896","key":"473_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht\u00a0S, Cipriani\u00a0A, Spineli\u00a0L, Mavridis\u00a0D, Orey\u00a0D, Richter\u00a0F, Samara\u00a0M, Barbui\u00a0C, Engel\u00a0RR, Geddes\u00a0JR, Kissling\u00a0W, Stapf\u00a0MP, L\u00e4ssig\u00a0B, Salanti\u00a0G, Davis\u00a0JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a\u00a0multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"}],"container-title":["neuropsychiatrie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40211-023-00473-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40211-023-00473-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40211-023-00473-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T13:17:19Z","timestamp":1694179039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40211-023-00473-0"}},"subtitle":["Monitoring und Rechallenge\u00a0\u2013 eine narrative \u00dcbersicht","Monitoring and rechallenge \u2013 a narrative review"],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1007\/s40211-023-00473-0","relation":{},"ISSN":["0948-6259","2194-1327"],"issn-type":[{"type":"print","value":"0948-6259"},{"type":"electronic","value":"2194-1327"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.J.\u00a0Berger und A.\u00a0Hofer geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}